Departments of Gastroenterology, Hepatology and Nutrition.
Center for Population Health Research and Quantitative Health Sciences.
J Clin Gastroenterol. 2021 Apr 1;55(4):343-349. doi: 10.1097/MCG.0000000000001364.
Data from standard definition colonoscopy era demonstrate patients with an advanced adenoma (≥10 mm, villous features or high-grade dysplasia) or ≥3 nonadvanced adenomas are considered high-risk for metachronous advanced neoplasia (MAN). Low-risk adenoma (LRA) patients are those with 1 to 2, <10 mm tubular adenomas. High definition colonoscopy, split-dose bowel preparation, and attention to adenoma detection enhance diminutive adenoma detection. We compared baseline adenoma characteristics between patients undergoing colonoscopy in a historic cohort (HC) and contemporary cohort (CC) to determine if number of patients with ≥3 nonadvanced adenomas are increased in CC, and if those features are associated with MAN in CC.
Patients undergoing their first colonoscopy in HC (<2006) and CC (≥2006) at age 50 and above were identified through natural language processing. Multivariable regression analysis compared baseline adenoma characteristics between HC and CC, and determined the association between baseline characteristics and MAN in CC patients.
In total, 255,074 colonoscopies were performed between 1990 and 2015. A total of 9773 colonoscopies performed in the HC and 59,531 in the CC were included. At baseline, CC patients were more likely to have ≥3 nonadvanced adenomas [odds ratio (OR): 2.1, 95% confidence interval (CI): 1.7-2.6]. In 3,377 CC patients undergoing follow-up colonoscopy, the risk of MAN did not differ between patients with LRA versus those with ≥3 nonadvanced adenomas (6.3% vs. 4.6%, OR: 1.4, CI: 0.58-3.5) including 3-4 (6.1%, OR: 1.4, CI: 0.52-3.6) and ≥5 (7.7%, OR: 1.8, CI: 0.23-14.6), although few patients had ≥5 nonadvanced adenomas.
Colonoscopy in the contemporary era increases detection of patients with ≥3 nonadvanced adenomas, which do not increase the risk of MAN compared with LRA patients. A similar surveillance to LRA patients should be considered for those patients.
来自标准定义结肠镜检查时代的数据表明,患有高级腺瘤(≥10mm,绒毛状特征或高级别异型增生)或≥3 个非高级腺瘤的患者被认为是同时性高级别肿瘤(MAN)的高危人群。低危腺瘤(LRA)患者是指有 1 至 2 个,<10mm 的管状腺瘤。高清结肠镜检查、分次肠道准备以及对腺瘤检测的关注可提高微小腺瘤的检出率。我们比较了历史队列(HC)和当代队列(CC)中接受结肠镜检查的患者的基线腺瘤特征,以确定 CC 中≥3 个非高级腺瘤的患者数量是否增加,以及这些特征是否与 CC 中的 MAN 相关。
通过自然语言处理,确定了 1990 年至 2015 年期间在 HC(<2006 年)和 CC(≥2006 年)中首次接受结肠镜检查的患者。多变量回归分析比较了 HC 和 CC 患者的基线腺瘤特征,并确定了 CC 患者基线特征与 MAN 之间的关联。
总共进行了 255074 例结肠镜检查。共纳入 9773 例 HC 和 59531 例 CC 的结肠镜检查。基线时,CC 患者更有可能存在≥3 个非高级腺瘤[比值比(OR):2.1,95%置信区间(CI):1.7-2.6]。在 3377 例接受随访结肠镜检查的 CC 患者中,LRA 患者与≥3 个非高级腺瘤患者的 MAN 风险无差异(6.3%比 4.6%,OR:1.4,CI:0.58-3.5),包括 3-4 个(6.1%,OR:1.4,CI:0.52-3.6)和≥5 个(7.7%,OR:1.8,CI:0.23-14.6),尽管少数患者有≥5 个非高级腺瘤。
在当代,结肠镜检查增加了≥3 个非高级腺瘤患者的检出率,与 LRA 患者相比,这并未增加 MAN 的风险。对于这些患者,应考虑与 LRA 患者相似的监测。